Article Text

PDF
Cohort study
Ranitidine use is associated with increased morbidity and mortality in very low birthweight infants
  1. C Michael Cotten,
  2. William F Malcolm
  1. Department of Pediatrics-Neonatology, Duke University, Durham, North Carolina, USA
  1. Correspondence to: C Michael Cotten
    Pediatrics-Neonatology, Duke University, 2424 Erwin Road suite 504, Durham, NC 27705, USA; cotte010{at}mc.duke.edu

Statistics from Altmetric.com

Commentary on: OpenUrlAbstract/FREE Full Text

Context

Gastroesophageal reflux (GER) is the retrograde movement of stomach contents into the oesophagus. Pharmacotherapy aimed at reducing problems attributed to GER includes histamine receptor blockers (H2 blockers), such as ranitidine, which reduce stomach acidity. Extremely preterm infants often exhibit clinical signs consistent with GER,1 and GER medications are among the most commonly prescribed medications in neonatal intensive care units (NICUs).2

Approximately one third of extremely premature (<28 weeks gestation), very low birthweight (VLBW; <1500 g) infants acquire infections during their NICU stay. Necrotising enterocolitis (NEC), a serious intestinal morbidity in preterm infants, occurs in approximately 10%. About half …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.